Collect Product
Product Details
Source
Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 is a mouse monoclonal antibody derived from hybridoma cells fused with SP2/0 myeloma cells and murine B lymphocytes.
Antibody Type
Hybridoma Monoclonal
Isotype
Mouse IgG1, Kappa
Immunogen
DM-1
Specificity
This monoclonal antibody specifically recognizes both DM-1 and DM-4.
Purification
Protein A purified / Protein G purified.
Concentration
Please refer to the Certificate of Analysis (CoA).
Form
Lyophilized
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
Shipping
Lyophilized product is shipped at ambient temperature.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Notices
Product Specific Notices: For research use only.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
Bioactivity-ELISA
Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).
Protocol
Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 2 μg/mL, add increasing concentrations of Trastuzumab-DM1 (T-DM1), and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 8 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.5 ng/mL (Routinely tested).
Protocol
Serial dilutions of DM1 were added into Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73): Trastuzumab-DM1 binding reactions. The half maximal inhibitory concentration (IC50) is 0.148 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration.
Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) is specific to Trastuzumab-DM1 and has no cross-reactivity with Trastuzumab Deruxtecan, Disitamab Vedotin (RC48), Trastuzumab MMAE and Sacituzumab Govitecam (Routinely tested).
User Reviews Publish Comment
Contact Us
Drug Candidate Licensing
